🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 17 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
08/02/2016 24,30 24,84 22,65 23,37 -5,12% 9,03% 936.700
05/02/2016 26,45 26,89 24,11 24,63 -7,75% 10,51% 779.100
04/02/2016 24,90 27,72 24,88 26,70 +6,12% 11,41% 793.400
03/02/2016 24,24 25,34 23,29 25,16 +4,88% 8,44% 679.000
02/02/2016 24,20 24,70 23,60 23,99 -3,03% 4,55% 584.200
01/02/2016 23,82 25,09 22,80 24,74 +3,86% 9,61% 590.500
29/01/2016 23,00 24,55 22,79 23,82 +3,43% 7,66% 664.500
28/01/2016 24,51 24,60 22,31 23,03 -4,40% 9,34% 953.700
27/01/2016 26,00 26,23 23,70 24,09 -7,63% 9,73% 926.000
26/01/2016 25,96 26,71 24,71 26,08 +1,05% 7,70% 654.700
25/01/2016 26,96 27,62 25,44 25,81 -6,32% 8,10% 1.293.400
22/01/2016 27,59 28,90 26,70 27,55 +2,53% 7,97% 545.300
21/01/2016 26,75 29,35 26,56 26,87 -0,99% 10,43% 1.236.500
20/01/2016 23,91 28,26 22,79 27,14 +10,73% 22,88% 1.324.600
19/01/2016 23,76 26,20 23,12 24,51 +6,06% 12,96% 1.889.200
15/01/2016 21,43 23,66 18,63 23,11 -3,02% 23,47% 3.401.900
14/01/2016 22,65 24,39 20,61 23,83 +5,16% 16,69% 1.096.000
13/01/2016 24,06 24,47 21,44 22,66 -5,07% 12,59% 912.300
12/01/2016 23,32 24,54 22,03 23,87 +2,98% 10,76% 755.500
11/01/2016 26,50 26,59 22,61 23,18 -11,93% 15,02% 979.500
08/01/2016 28,19 28,69 26,14 26,32 -4,19% 9,05% 714.900
07/01/2016 28,49 29,25 27,23 27,47 -6,28% 7,09% 1.231.200
06/01/2016 28,94 29,86 28,58 29,31 -0,85% 4,42% 890.600
05/01/2016 31,04 31,62 29,13 29,56 -4,21% 8,02% 659.300
04/01/2016 31,60 31,89 30,09 30,86 -4,75% 5,70% 751.300
31/12/2015 32,61 33,00 31,80 32,40 -0,89% 3,68% 362.900
30/12/2015 33,46 34,65 32,58 32,69 -2,53% 6,19% 353.000
29/12/2015 32,57 33,71 32,45 33,54 +3,36% 3,87% 334.600
28/12/2015 32,69 33,18 31,75 32,45 +0,03% 4,37% 430.600
24/12/2015 33,45 33,92 32,36 32,44 -3,16% 4,65% 287.500